During the meetings, Maze Therapeutics will present additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, as well as preclinical research supporting inhibition of SLC6A19 to slow ...

Appointed key leadership to drive (Z)-endoxifen development and evolve pathway to commercialization SEATTLE, /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a ...

Good morning, everyone, and welcome, everyone, to the Prelude Therapeutics Investor Conference Call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now ...

A new study found that walking just a few thousand steps daily can significantly delay Alzheimer’s symptoms.

Q3 market update for the London Company Large Cap portfolio. Review performance vs. the Russell 1000, key stock drivers, and ...

From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA ...

Neighbors complained about noise, security guards, and hordes of traffic. An unlicensed school named after the Zuckerbergs’ ...

COPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing ...

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept ...

Q3 2025 Earnings Call Transcript November 10, 2025 908 Devices Inc. misses on earnings expectations. Reported EPS is $-0.15 ...

Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities ...

A longstanding push for urgent action on environmental toxins is landing in an unprecedented time in American politics.